MaiselASKrishnaswamyPNowakRM. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med2002; 347: 161–167.
2.
DavisMEspinerERichardsG. Plasma brain natriuretic peptide in assessment of acute dyspnea. Lancet1994; 343: 440–444.
3.
PotockiMBreidthardtTReichlinT. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in the diagnosis of heart failure. J Intern Med2010; 267: 119–129.
4.
LainchburyJGCampbellEFramptonCM. Brain natriuretic peptide and N-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol2003; 42: 728–735.
5.
JanuzziJLvan RimmenadeRLainchburyJ. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients. The International Collaborative of NT-proBNP Study. Eur Heart J2006; 27: 330–337.
6.
McCulloughPANowakRMMcCordJ. B-type natriuretic peptide and clinical judgement in emergency diagnosis of heart failure. Analysis from Breathing Not Properly (BNP) multinational study. Circulation2002; 106: 416–422.
7.
MuellerCScholerALaule-KilianK. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med2004; 350: 647–654.
8.
MoeGWHowlettJJanuzziJL. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation2007; 115: 3103–3110.
9.
SchneiderHGLamLLokugeA. BNP testing, clinical outcomes, and health services use in emergency department patients with dyspnoea. Ann Intern Med2009; 150: 365–371.
10.
RuttenJHSteyerbergEWBoomsmaF. NT-proBNP testing in the emergency department: beneficial effects on hospitalization, costs and outcome. Am Heart J2008; 156: 71–77.
11.
LamLLCameronPASchneiderHG. Meta-analysis: effect of B-type natriuretic peptide testing on clinical outcomes in patients with acute dyspnea in the emergency setting. Ann Intern Med2010;153(11): 728–735.
12.
MuellerCLaule-KilianKSchindlerC. Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea. Arch Intern Med2006; 166: 1081–1087.
13.
BreidthardtTLauleKStrohmeyerAH. Medical and economic long-term effects of B-type natriuretic peptide testing in patients with acute dyspnea. Clin Chem2007; 53: 1415–1422.
14.
MaiselAMuellerCNowakR. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol2010; 55: 2062–2076.
KucherNPrintzenGGoldhaberSZ. Prognostic role of BNP in acute pulmonary embolism. Circulation2003; 107: 2545–2547.
17.
de LermosJAMorrowDABentleyJH. The prognostic value of BNP in patients with acute coronary syndromes. N Engl J Med2001; 345: 1014–1021.
18.
MeiselSRJanuzziJLMedvedowskiM. Pre-admission NT-proBNP improves diagnostic yield and risk stratification – the NT-proBNP for EValuation of dyspneic patients in the Emergency Room and hospital [BNP4EVER] study. Acute Cardiovas Care2012.
19.
FelkerGMHasselbladVHernandezAF. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J2009; 158: 422–430.
20.
ThygesenKMairJMuellerC. Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. Eur Heart J2011 [Epub ahead of print].
